文献速递真菌感染医院感染防控

肺移植后侵袭性真菌感染:抗真菌预防背景下的流行病学

Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该前瞻性队列研究纳入2007年1月至2014年10月单中心815例肺移植受者,移植住院期间标准预防为雾化两性霉素B脂质复合物。移植后180天内侵袭性真菌感染患病率为19.1/100例手术(95%CI 16.4-21.8),侵袭性念珠菌病为11.4%,非念珠菌IFIs为8.8%。

要点

  • 肺移植后180天内侵袭性真菌感染患病率19.1/100例手术。
  • 侵袭性念珠菌病中位发生31天,非念珠菌IFIs中位86天。
  • 72%的IFIs发生于未近期使用抗真菌预防时。

核心结论

  • 尽管移植住院期间使用雾化两性霉素B脂质复合物预防,肺移植受者侵袭性真菌感染发生率仍高。
  • 数据提示移植后90天内针对念珠菌的系统性预防及延长至180天的抗霉菌预防可能有益。

研究设计与样本

  • 前瞻性收集2007年1月至2014年10月单中心三级学术医院所有肺移植受者临床数据。
  • 共815例肺移植受者,其中156例发生侵袭性真菌感染。
  • 标准抗真菌预防为移植住院期间雾化两性霉素B脂质复合物。
  • 分析移植后180天内IFIs患病率、发生时间、危险因素及突破性感染数据。

主要发现

  • 156/815例受者发生IFIs,患病率19.1/100例手术(95%CI 16.4-21.8%)。
  • 侵袭性念珠菌病患病率11.4%(95%CI 9.2-13.6%),非念珠菌IFIs为8.8%(95%CI 6.9-10.8%)。
  • 首次侵袭性念珠菌病中位发生时间为移植后31天(IQR 16-56天),非念珠菌IFIs中位86天(IQR 40-121天)。
  • 169次IFIs中121次(72%)发生于未近期使用抗真菌预防时。
  • 突破性侵袭性念珠菌病多与米卡芬净预防失败相关(n=16),突破性非念珠菌IFIs多与雾化两性霉素B预防失败相关(n=24)。

临床怎么用

  • 肺移植后需关注侵袭性念珠菌病(早期,中位31天)及非念珠菌IFIs(较晚,中位86天)。
  • 雾化两性霉素B脂质复合物住院期间预防下仍可见突破性IFIs,尤其米卡芬净及雾化两性霉素B预防失败。
  • 可考虑移植后90天内针对念珠菌的系统性预防及延长至180天的抗霉菌活性预防。

局限性

  • 单中心三级学术医院研究,结果外推需谨慎。
  • 预防方案为移植住院期间雾化两性霉素B脂质复合物,其他预防策略下的适用性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung transplant recipients commonly develop invasive fungal infections (IFIs), but the most effective strategies to prevent IFIs following lung transplantation are not known. METHODS: We prospectively collected clinical data on all patients who underwent lung transplantation at a tertiary care academic hospital from January 2007-October 2014. Standard antifungal prophylaxis consisted of aerosolized amphotericin B lipid complex during the transplant hospitalization. For the first 180 days after transplant, we analyzed prevalence rates and timing of IFIs, risk factors for IFIs, and data from IFIs that broke through prophylaxis. RESULTS: In total, 156 of 815 lung transplant recipients developed IFIs (prevalence rate, 19.1 IFIs per 100 surgeries, 95% confidence interval [CI] 16.4-21.8%). The prevalence rate of invasive candidiasis (IC) was 11.4% (95% CI 9.2-13.6%), and the rate of non-Candida IFIs was 8.8% (95% CI 6.9-10.8%). First episodes of IC occurred a median of 31 days (interquartile range [IQR] 16-56 days) after transplant, while non-Candida IFIs occurred later, at a median of 86 days (IQR 40-121 days) after transplant. Of 169 IFI episodes, 121 (72%) occurred in the absence of recent antifungal prophylaxis; however, IC and non-Candida breakthrough IFIs were observed, most often representing failures of micafungin (n = 16) and aerosolized amphotericin B (n = 24) prophylaxis, respectively. CONCLUSIONS: Lung transplant recipients at our hospital had high rates of IFIs, despite receiving prophylaxis with aerosolized amphotericin B lipid complex during the transplant hospitalization. These data suggest benefit in providing systemic antifungal prophylaxis targeting Candida for up to 90 days after transplant and extending mold-active prophylaxis for up to 180 days after surgery.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Baker AW, Maziarz EK, Arnold CJ, et al. Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. Clin Infect Dis. 2020. PMID: 30801642. doi:10.1093/cid/ciz156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。